Impact of Omega-3 Fatty Acids on Lactate

Ege University

Status: Completed

Conditions: Gastric Surgery

Treatments: Drug: Lipovenoes® 10% and Omegaven®,

Study type: Interventional

Funder types: Other

Identifiers

NCT00929461

B.30.2.EGE.0.01.00.00/7EM/458

Details and patient eligibility

About

Pre- and intra-operative nutritional support in patient undergoing major surgery results in decreased morbidity and mortality. Studies investigating the role of omega-3 fatty acids in these patients are increasing. Some are focused on perfusion at the cellular level. This study was undertaken to address the effect of postoperative administration of omega-3 fatty acids on cellular hypoperfusion associated with major gastric surgery.

Sex: All

Ages: 25 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing major gastric cancer surgery

Exclusion criteria

• None

Trial design

0 participants in 2 patient groups

Omega-3 group

Other group

Description:

All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.

Treatment:

Drug: Lipovenoes® 10% and Omegaven®,

Omega 3 + Omega 6 group

Other group

Description:

All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.

Treatment:

Drug: Lipovenoes® 10% and Omegaven®,